Cost-effectiveness analysis of vaccination against Covid-19 in China
Bibliographic Data
| ID | 22067476 |
|---|---|
| Authors | Huixuan Zhou (0000-0002-7018-6918, Beijing Sport University), Ningxin Ding (0000-0002-1735-154X, Victoria University of Wellington, corresponding author), Xueyan Han (0000-0002-6847-9682, Chinese Academy of Medical Sciences & Peking Union Medical College), Hanyue Zhang (0000-0003-1947-3310, Northeast Normal University), Zeting Liu (0000-0003-1340-2941, Beijing Sport University), Xiao Jia (0000-0002-6888-6560, Beijing Sport University), Jingjing Yu (0000-0001-8938-4298, Beijing Sport University), Wei Zhang (0000-0002-5458-9581, National Institutes for Food and Drug Control) |
| Year | 2023 |
| Volume | 11 |
| Pages | 1037556-1037556 |
| Publication date | 2023-03-07 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1037556 |
| PMID | 36960359 |
| OpenAlex | W4323363977 |
| Language | EN |
| Citations received | 1 |
| References cited | 28 |
Introduction: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. Methods: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. Results: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. Conclusion: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses
2019-20 coronavirus outbreak · Betacoronavirus · China · Data science · Geography · Outbreak · Pandemic · Vaccination · Computer Science · COVID-19 epidemiological studies · Medicine · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Virology
| Unique citing works | 1 |
|---|---|
| Citations per year | 0.5 |
| Citation span | 2024 - 2024 (1) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 1 |